Clinical Trial News and Research

RSS

Tornier and LifeCell commence enrollment in Conexa Reconstructive Tissue Matrix clinical trial

Tornier, Inc., a global leader in extremities and sports medicine orthopaedics, and LifeCell™ Corporation, a KCI Company, announced today the first 13 patients have been enrolled in a multi-center clinical trial to document the clinical value of Conexa™ Reconstructive Tissue Matrix for the surgical repair of large rotator cuff tears. Conexa™ is a porcine-derived tissue matrix with both biologic and mechanical properties that are important to support the repair of injured or surgically reconstructed soft tissue. Launched by Tornier for orthopaedic applications in October of 2008, Conexa™ has been used successfully in approximately 1,500 patients.

28 Jan 2010

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX168, an orally-administered small molecule designed to treat autoimmune diseases.

28 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

EnteroMedics to submit an IDE application for next-generation Maestro RC System

EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that, following a recent meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company’s EMPOWER™ study results and the regulatory process, the Company intends to submit an Investigational Device Exemption (IDE) application for a clinical trial to support a possible Premarket Approval (PMA) application for the next-generation Maestro® RC System in the treatment of morbid obesity.

28 Jan 2010

Neovasc to fund proceeds of its non-brokered private placement for COSIRA trial

Neovasc Inc. today announced that it has completed the first tranche of a previously announced non-brokered private placement of approximately 7.4 million units at the price of $0.27 per unit for aggregate gross proceeds of up to $2.0 million.

28 Jan 2010

Cenduit announces strategic business alliance with invivodata

Cenduit, LLC, and invivodata, inc., today announce a strategic business alliance to further improve clinical trial efficiencies by adding the scientific and operational benefits of invivodata’s electronic Patient Reported Outcomes (ePRO) solutions to the proven efficiencies of Cenduit‘s Interactive Response Technology solution (IRT).

28 Jan 2010

Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

Idera Pharmaceuticals, Inc. today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9.

28 Jan 2010

ACM Global Central Laboratory launches enhanced version of its proprietary LabStar system

ACM Global Central Laboratory, the global central lab that continually defines the customer-service standard with its flexible approach, has launched an enhanced version of its proprietary LabStarSM system, which captures all clinical trial testing data in a single location for easy access and comprehensive reporting.

28 Jan 2010

Studies in Mexico and Africa demonstrate the effectiveness of rotavirus vaccine

For the first time ever, studies in Mexico and Africa, published today in the New England Journal of Medicine, demonstrate a reduction in diarrheal disease deaths following rotavirus vaccine introduction in Mexico and vaccine efficacy among impoverished populations in Malawi and South Africa.

28 Jan 2010

Orthopaedic researchers explore novel treatments for wounded soldiers

For each action, there is an equal and opposite reaction. So after the surge in U.S. troops heading to Afghanistan, there will be an influx of injured veterans returning back home. But the U.S. Department of Defense has recruited its own "soldiers" in the battle against war casualties: a consortium of researchers who are improving care to wounded soldiers as well as the general public.

28 Jan 2010

PHT announces enhanced StudyWorks portal for clinical trial management

PHT Corporation continues to drive the ePRO (electronic patient reported outcome) industry forward. The company today announced an enhanced StudyWorks™ portal that offers study sponsors an unprecedented level of management and logistical control over their clinical trials. PHT is the leading provider of ePRO solutions used in more than 400 clinical trials worldwide.

28 Jan 2010

New report illustrates why cardiovascular disease is under-recognized and under-treated in women

Today, the Society for Cardiovascular Angiography and Interventions (SCAI) launched "WINHeart -- Score a WIN for Women," an initiative that raises awareness surrounding gender-based disparities in the diagnosis, treatment and survival of women with cardiovascular disease (CVD).

28 Jan 2010

Special issue explores how evolution can help doctors understand and treat diseases

What does evolution - a field that often deals with changes over many generations - have to do with preventing and treating disease in our lifetime?

28 Jan 2010

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces positive results from a recently completed clinical trial demonstrating the activity of GFT505 on glucose homeostasis. Results from the clinical trial (GFT505-2094) clearly demonstrate the potential of the drug candidate to reduce global cardiovascular risk in prediabetic patients who suffer from impaired fasting plasma glucose, impaired glucose tolerance, and abdominal obesity.

28 Jan 2010

Amarin reviews 2009 accomplishments; outlines strategy for 2010 and beyond

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today issued a special letter to its shareholders.

28 Jan 2010

Seroquel XR's FDA approval does not change Decision Resources' earlier antipsychotics market forecast

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the recent decision by the U.S. Food and Drug Administration (FDA) to grant approval of AstraZeneca's Seroquel XR for adjunctive treatment of major depressive disorder will not change Decision Resources' market forecast for the indication. As previously forecasted, Seroquel and Seroquel XR will garner nearly one quarter of antipsychotics sales as adjunctive treatments for major depressive disorder in 2013 in the world's major pharmaceutical markets.

28 Jan 2010

Santica Research Labs launches CelluScience Anti-Cellulite Beaute Intensive dietary supplement

More than 85% of women in the U.S. have cellulite. Now, there is a revolutionary new anti-cellulite dietary supplement clinically proven to help target the thighs, hips and gluteal area.

28 Jan 2010

Scientists uncover a key cellular mechanism that alters brain cell function in Huntington's disease

Scientists at the Brain Research Centre and Centre for Molecular Medicine and Therapeutics have uncovered a key cellular mechanism that alters brain cell function in Huntington's disease, and identified a possible treatment for the disease.

28 Jan 2010

PRA International enters into partnership agreement with Oncopartners and IBPC

PRA International, a leading Clinical Research Organization, announces it has entered into a partnership agreement with Oncopartners, a leading Latin American oncology development company, and its exclusive partner IBPC, a non-profit oncology research network comprised of Brazil's largest public oncology hospitals which collectively treat an estimated 140,000 new incidences of cancer annually.

28 Jan 2010

Abbott declares quarterly dividend of 40 cents per share

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2009.

27 Jan 2010

Clinical Trial News and Research

Tornier and LifeCell commence enrollment in Conexa Reconstructive Tissue Matrix clinical trial

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

Ligand Pharmaceuticals acquires Metabasis Therapeutics

EnteroMedics to submit an IDE application for next-generation Maestro RC System

Neovasc to fund proceeds of its non-brokered private placement for COSIRA trial

Cenduit announces strategic business alliance with invivodata

Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

ACM Global Central Laboratory launches enhanced version of its proprietary LabStar system

Studies in Mexico and Africa demonstrate the effectiveness of rotavirus vaccine

Orthopaedic researchers explore novel treatments for wounded soldiers

PHT announces enhanced StudyWorks portal for clinical trial management

New report illustrates why cardiovascular disease is under-recognized and under-treated in women

Special issue explores how evolution can help doctors understand and treat diseases

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

Amarin reviews 2009 accomplishments; outlines strategy for 2010 and beyond

Seroquel XR's FDA approval does not change Decision Resources' earlier antipsychotics market forecast

Santica Research Labs launches CelluScience Anti-Cellulite Beaute Intensive dietary supplement

Scientists uncover a key cellular mechanism that alters brain cell function in Huntington's disease

PRA International enters into partnership agreement with Oncopartners and IBPC

Abbott declares quarterly dividend of 40 cents per share

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer